Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

Authors

Institutions

Publication Details

Journal
Eurosurveillance
Published
2025-02-20
DOI
https://doi.org/10.2807/1560-7917.es.2025.30.7.2500074
Citations
6
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
8.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

Thomas Duret, François Blanquart, A Jacques, Marta Coelho Nunes et al.
6 citations
Eurosurveillance
Influenza Virus Research Studies
8.13
article

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

Thomas Duret, François Blanquart, A Jacques, Marta Coelho Nunes, Vincent Enouf, Bruno Lina, Antonin Bal, Laurence Josset, Vincent Vieillefond, Claire Nour Abou Chakra, Stéphanie Haïm‐Boukobza, Benoit Visseaux, Marie Anne Rameix-Welti, Guillaume Deleglise, Valentin Wehrle
article en
6 citations

Abstract

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

EurosurveillanceVol. 30(7)
Université Claude Bernard Lyon 1 (FR), South African Medical Research Council (ZA), École Normale Supérieure de Lyon (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Institut Pasteur (FR), Collège de France (FR), University of the Witwatersrand (ZA), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Université Paris Sciences et Lettres (FR), Hospices Civils de Lyon (FR), Centre Interdisciplinaire de Recherche en Biologie (FR), Virologie et Pathologies Humaines (FR), The Design Knowledge Company (United States) (US), Centre International de Recherche en Infectiologie (FR), Infection et inflammation (FR), Virbac (France) (FR)
Good health and well-being
Openalex Percentile: Top 3%
Influenza Virus Research Studies
8.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.